Format

Send to

Choose Destination
See comment in PubMed Commons below
Urol Int. 2013;90(4):435-8. doi: 10.1159/000345489. Epub 2013 Jan 18.

Adrenocortical carcinoma: clinicopathological features, prognostic factors and outcome.

Author information

  • 1Department of Medical Oncology, Institute of Oncology, University of Istanbul, Istanbul, Turkey. drkeskin76@hotmail.com

Abstract

OBJECTIVE:

The purpose of this study was to investigate the clinicopathological characteristics and treatment outcomes of patients with adrenocortical carcinoma (AC).

METHODS:

Twenty-four patients (10 females and 14 males) diagnosed with AC between 1998 and 2009 were evaluated. Clinical features and outcomes were reviewed.

RESULTS:

Median age was 46.5 years. One (4%) patient was classified as stage I, 10 (42%) were classified as stage II, 8 (33%) were classified as stage III and 5 (21%) were classified as stage IV. Tumor sizes ranged from 3 to 22 cm with a mean diameter of 11 cm. Five patients were locally inoperable at initial diagnosis. In addition to surgery, 2 of 19 patients were treated with an adjuvant cisplatin plus etoposide regimen. Sixteen patients were treated with chemotherapy after recurrence. Median survival time was 18 months. The 1- and 5-year overall survival estimates were 73 and 48%, respectively. Mean survival times for male and female patients were 58 and 12 months, respectively (p = 0.046). Early T stage (p = 0.04), lymph node negativity (p < 0.001), the absence of distant metastases (p < 0.001) and early stage (p < 0.001) were correlated with overall survival.

CONCLUSION:

AC is a rare disease with a poor prognosis. There are correlations between gender, stage and survival.

Copyright © 2013 S. Karger AG, Basel.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland
    Loading ...
    Write to the Help Desk